Last $0.08 USD
Change Today -0.003 / -3.75%
Volume 2.3M
AMBS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

amarantus bioscience holding (AMBS) Snapshot

Open
$0.08
Previous Close
$0.08
Day High
$0.08
Day Low
$0.08
52 Week High
07/29/14 - $0.20
52 Week Low
12/1/14 - $0.05
Market Cap
61.6M
Average Volume 10 Days
2.2M
EPS TTM
$-0.05
Shares Outstanding
799.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARANTUS BIOSCIENCE HOLDING (AMBS)

Related News

No related news articles were found.

amarantus bioscience holding (AMBS) Related Businessweek News

No Related Businessweek News Found

amarantus bioscience holding (AMBS) Details

Amarantus BioScience Holdings, Inc., a biotechnology company, engages in discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. Its lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is a targeted therapeutic to address the underlying programmed cell death (apoptosis) associated with a range of devastating human disorders with a priority to identify drug able orphan indications, including Retinitis Pigmentosa. The company’s principal products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and Eltoprazine, a small molecule drug candidate, which is used for the treatment of Parkinson’s disease medication Levadopa-Induced Dyskinesia and Adult Attention Deficit Hyperactivity Disorders that is in Phase II clinical trials. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

3 Employees
Last Reported Date: 06/20/14
Founded in 2008

amarantus bioscience holding (AMBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $230.1K
Vice President of Financial Operations, Corpo...
Total Annual Compensation: $261.0K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $213.8K
Compensation as of Fiscal Year 2013.

amarantus bioscience holding (AMBS) Key Developments

Amarantus Bioscience Holdings, Inc. Appoints Elise Brownell as Senior Vice President of Operations and Project Management

Amarantus Bioscience Holdings Inc. announced the appointment of Elise Brownell to the newly created position of Senior Vice President of Operations and Program Management. Dr. Brownell brings more than 20 years of biotechnology and pharmaceutical project management experience with a track record of advancing programs through clinical development. She serves as a Life Sciences entrepreneurial advisor for ASTIA. Dr. Brownell is also a member of the Editorial Advisory Board for Contract Pharma Magazine, and previous Chair of the Leaders Network program of Women in Consulting.

Amarantus Appoints Joseph Rubinfeld to its Board of Directors

Amarantus BioScience Holdings Inc. announced the appointment of Joseph Rubinfeld, Ph.D. to its Board of Directors. Dr. Rubinfeld is a renowned expert in the field of drug development, and a co-founder of Amgen, one of the most successful companies in the history of the biotechnology industry. Dr. Rubinfeld brings more than 40 years of biopharmaceutical leadership experience to Amarantus' Board of Directors. Dr. Rubinfeld is currently a Board member of Regenicin Inc. and CytRx Corporation.

Amarantus BioScience Holdings, Inc. Announces Positive Effects of Mesencephalic-Astrocyte-Derived Neurotrophic Factor

Amarantus BioScience Holdings Inc. announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). MANF was discovered utilizing Amarantus' proprietary PhenoGuard(TM) Protein Discovery Engine. The aim of the study was to evaluate the efficacy of protecting visual acuity by a single intravitreal injection of MANF in the rd10/rd10 genetic mouse model of RP. These animals carry a spontaneous missense point mutation in Pde6b (cGMP phosphodiesterase 6B, rod receptor, beta polypeptide). Mutations in this gene are found in human autosomal recessive RP. Visual acuity was determined by measuring the spatial frequency threshold by optokinetic tracking. This method allows for a non-invasive assessment of visual acuity in rodents and higher species, including humans. A single intravitreal administration of MANF after the onset of retinal degeneration on Day 31 resulted in a statistically significant protective effect on visual acuity on Day 38 and Day 45, as compared to vehicle treated animals. This is the first observation of MANF providing a functional benefit on vision in a model of RP. These data complement previously announced effects of MANF on preserving retinal morphology in RP models. The experiments were conducted at a ophthalmology contract research laboratory. MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBS:US $0.08 USD -0.003

AMBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBS.
View Industry Companies
 

Industry Analysis

AMBS

Industry Average

Valuation AMBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.